Lantheus Holdings Inc
$ 97.13
-2.19%
01 Jun - close price
- Market Cap 6,323,753,000 USD
- Current Price $ 97.13
- High / Low $ 100.75 / 96.75
- Stock P/E 23.18
- Book Value 18.63
- EPS 4.19
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.24 %
- 52 Week High 103.89
- 52 Week Low 47.25
About
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Analyst Target Price
$105.23
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-07-31 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 |
| Reported EPS | 1.46 | 1.67 | 1.27 | 1.57 | 1.02 | 1.59 | 1.7 | 1.8 | 1.69 | 1.75 | 1.47 | 1.54 |
| Estimated EPS | 1.23 | 1.16 | 1.27 | 1.68 | 1.23 | 1.5431 | 1.56 | 1.83 | 1.54 | 1.45 | 1.32 | 1.31 |
| Surprise | 0.23 | 0.51 | 0 | -0.11 | -0.21 | 0.0469 | 0.14 | -0.03 | 0.15 | 0.3 | 0.15 | 0.23 |
| Surprise Percentage | 18.6992% | 43.9655% | 0% | -6.5476% | -17.0732% | 3.0393% | 8.9744% | -1.6393% | 9.7403% | 20.6897% | 11.3636% | 17.5573% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.29 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LNTH
2026-06-02 12:09:37
Lantheus' investigational thrombus-imaging agent, LNTH-2513 (18F-GP1) PET/CT, has been awarded the SNMMI’s 2026 Image of the Year. This recognition stems from a 46-patient study for suspected lower-extremity deep vein thrombosis (DVT), where LNTH-2513 demonstrated high diagnostic accuracy and was well-tolerated. The imaging agent shows great potential for thrombus-specific visualization, identifying concomitant pulmonary embolism in a significant number of patients.
2026-06-02 12:09:37
Lantheus Holdings, Inc. announced that an image generated using LNTH-2513 (18F-GP1) PET/CT was awarded SNMMI’s Image of the Year at the 2026 Annual Meeting. The recognition highlights the potential of this investigational imaging agent for detecting acute lower-extremity deep vein thrombosis (DVT), showing high diagnostic accuracy and the ability to detect thrombi in areas difficult to assess with conventional methods. LNTH-2513 (18F-GP1) is a fluorine-18-labeled PET imaging agent that selectively binds to activated platelets for direct visualization of active thrombus formation.
2026-05-31 13:09:57
Lantheus Holdings (LNTH) is gaining attention as new oncology data is set to be presented at ASCO 2026. Despite a recent pullback, the stock has shown strong momentum, with significant returns over the past year and five years. The company is considered undervalued by Simply Wall St's model, driven by its promising radiodiagnostic and royalty pipeline and upcoming product launches.
2026-05-31 00:39:02
Lantheus Holdings (LNTH) is gaining attention as new oncology data is set to be presented at the ASCO 2026 Annual Meeting. Despite recent stock gains, the company trades at a slight discount to analyst targets and its intrinsic value, driven by an expanding radiodiagnostic and royalty pipeline. Most financial models suggest LNTH is undervalued, with key risks including potential pricing pressure on PYLARIFY and slower adoption of new launches.
2026-05-29 11:11:16
Lantheus Holdings is set to present new clinical data for its radiopharmaceutical LNTH-2403 and real-world data for piflufolastat F 18 at the 2026 ASCO Annual Meeting. These presentations will offer insights into the company's osteosarcoma pipeline and the real-world adoption of its prostate cancer imaging agent, potentially influencing investor perceptions of its valuation and pipeline strength. The stock is currently trading around 5% below analyst consensus and is flagged as significantly undervalued by Simply Wall St.
2026-05-29 11:09:55
Lantheus Holdings is set to present new clinical data for LNTH-2403, an LRRC15-targeted radiopharmaceutical for osteosarcoma, and real-world data on piflufolastat F 18 for prostate cancer imaging at the 2026 ASCO Annual Meeting. These presentations will highlight the company's radiopharma pipeline and the adoption of its approved prostate cancer imaging agent, offering investors insights into its product breadth and research progress. Currently, the stock is trading below both analyst consensus and an estimated fair value, suggesting a potential valuation gap that these new data releases might address.
